HUTCHMED (China) Limited (NASDAQ:HCM) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of HUTCHMED (China) Limited (NASDAQ:HCM) by 99.0% during the 3rd quarter, HoldingsChannel reports. The firm owned 48,724 shares of the company’s stock after purchasing an additional 24,245 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in HUTCHMED were worth $952,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. lifted its holdings in HUTCHMED by 70.5% in the first quarter. Russell Investments Group Ltd. now owns 18,179 shares of the company’s stock valued at $304,000 after acquiring an additional 7,515 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its stake in HUTCHMED by 8.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 61,887 shares of the company’s stock worth $1,060,000 after purchasing an additional 4,877 shares in the last quarter. Rhumbline Advisers lifted its stake in HUTCHMED by 8.1% during the second quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock worth $129,000 after purchasing an additional 564 shares in the last quarter. Renaissance Technologies LLC lifted its stake in HUTCHMED by 74.8% during the second quarter. Renaissance Technologies LLC now owns 131,300 shares of the company’s stock worth $2,248,000 after purchasing an additional 56,200 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC lifted its stake in HUTCHMED by 9.7% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company’s stock worth $226,000 after purchasing an additional 1,168 shares in the last quarter. 8.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on HCM. The Goldman Sachs Group upped their price target on HUTCHMED from $17.00 to $19.00 and gave the stock a “neutral” rating in a research note on Thursday, August 1st. StockNews.com cut HUTCHMED from a “buy” rating to a “hold” rating in a research note on Monday, November 18th.

HUTCHMED Trading Up 6.0 %

NASDAQ:HCM opened at $18.43 on Thursday. The business’s fifty day moving average price is $18.80 and its 200 day moving average price is $18.52. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68. HUTCHMED has a 12 month low of $11.93 and a 12 month high of $21.92.

About HUTCHMED

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.